Top-line data from the immediate post-vaccination observation period of the trial will be reported in late second quarter of 2015. More than 300 patients from 17 institutions in
With these collaborations, Novartis will now have access to new CRISPR technology platforms for the discovery and development of new medicines. A clustered regularly interspaced short palindromic repeats
The Phase II trial is designed to evaluate the safety, efficacy and tolerability of KD025, the company’s orally bioavailable, potent and highly selective inhibitor of Rho-associated coiled-coiled kinase
Currently, the company is enrolling patients in its randomized, double-blind Phase IIb proof of concept trial designed to compare CVC to placebo in around 250 patients with NASH
In the trial, all healthy volunteers completed the treatment phase and results are scheduled to be released during the first quarter of 2015. The company is developing BL-8040
TRV130 is being developed as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain. The multicenter, randomized, double-blind, placebo- and active-controlled clinical trial is designed to evaluate
As part of the deal, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth about
Patient enrollment is scheduled to be completed by the end of January in this trial, which is being led by the Oxford Vaccine Group, part of the University
The open-label Phase II trial will enroll 54 patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL): 27 patients with diffuse large B-cell lymphoma and 27 with follicular lymphoma. Being carried
The company said that patients with advanced refractory solid tumors are being enrolled in the single-agent Phase Ia open-label dose-escalation trial. Currently, being conducted at four sites in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.